Metformin Improves the Prerequisites for FGF21 Signaling in Patients with Type 2 Diabetes.
Anne Kathrine Nissen PedersenLars Christian GormsenSøren NielsenNiels JessenMette BjerrePublished in: The Journal of clinical endocrinology and metabolism (2023)
Our findings suggest that metformin suppresses the circulating FAP activity and upregulate the expression of FGFR1c and β-klotho for increased FGF21-signalling in adipose tissue thus improving peripheral FGF21-sensitivity.